Keywords: Novartis, Secukinumab, AIN457, Plaque proriasis, Ph II

Novartis' secukinumab significantly effective in hard-to-treat plaque psoriasis

Article | 27 September 2012

Print This

Swiss drug major Novartis (NOVN: VX) this morning announced new Phase II data showing AIN457 (secukinumab) may significantly improve ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in